1Clinical Effectiveness Research Group, Oslo University Hospital and University of Oslo, Oslo, Norway
2Department of Transplantation Medicine, Oslo University Hospital, Oslo, Norway
3Digestive Disease Center, Showa University Northern Yokohama Hospital, Yokohama, Japan
© 2024 Korean Society of Gastrointestinal Endoscopy
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of Interest
Yuichi Mori has conflicts of interest with Olympus Corp. (consultancy and equipment on loan) and Cybernet System Corp. (loyalty fee). Natalie Halvorsen has no potential conflicts of interest.
Funding
None.
Author Contributions
Conceptualization: all authors; Data curation: all authors; Formal analysis: all authors; Supervision: YM; Writing–original draft: all authors; Writing–review & editing: all authors.
Standard | Leave-in-situ strategy | Resect-and-discard strategy |
---|---|---|
Negative predictive value (%) | ≥90b) | |
Sensitivity (%) | ≥90c) | ≥80d) |
Specificity (%) | ≥80c) | ≥80d) |
Agreement with post-polypectomy surveillance intervals (%) | ≥90a) |
Histopathology assessments are used as the gold standard.
ASGE, American Society for Gastrointestinal Endoscopy; ESGE, European Society of Gastrointestinal Endoscopy; PIVI, preservation and incorporation of valuable endoscopic innovations; SODA, simple optical diagnosis accuracy.
a)PIVI 1,
b)PIVI 2,
c)SODA 1,
d)SODA 2.
Year | Study | Modality | No. of subjects | No. of lesions | NPV (%) | Sensitivity (%) | Specificity (%) | Does CADx reach the PIVI and/or SODA thresholds (excluding surveillance interval recommendations)? |
---|---|---|---|---|---|---|---|---|
2013 | Aihara et al.13 | AFE | 32 | 102 | 85 | 94 | 89 | PIVI, no; SODA, N/A |
2015 | Kuiper et al.14 | AFE (WavStat4) | 87 | 171 | 78 | 87 | 55 | PIVI, no; SODA, N/A |
2016 | Rath et al.15 | AFE (WavStat4) | 27 | 137 | 96 | 85 | 81 | PIVI, no; SODA, no |
2016 | Kominami et al.16 | Magnifying NBI | 41 | 88 | 93 | 93 | 93 | PIVI, yes; SODA, yes |
2018 | Mori et al.17 | Endocytoscopy with NBI | 325 | 466 | 96 | 95 | 92 | PIVI, yes; SODA, yes |
2019 | Horiuchi et al.18 | AFE, NBI and white light imaging | 95 | 429 | 95 | 85 | 96 | PIVI, no; SODA, yes |
2022 | Barua et al.10 | Endocytoscopy with NBI | 518 | 892 | 93 | 90 | 86 | PIVI, yes; SODA, yes |
2022 | Minegishi et al.19 | NBI | 181 | 395 | 94 | 95 | 76 | PIVI, yes; SODA, no |
2023 | Rondonotti et al.12 | Blue light imaging | 389 | 596 | 91 | 89 | 88 | PIVI, yes; SODA, no |
Standard | Leave-in-situ strategy | Resect-and-discard strategy |
---|---|---|
Negative predictive value (%) | ≥90 |
|
Sensitivity (%) | ≥90 |
≥80 |
Specificity (%) | ≥80 |
≥80 |
Agreement with post-polypectomy surveillance intervals (%) | ≥90 |
Year | Study | Modality | No. of subjects | No. of lesions | NPV (%) | Sensitivity (%) | Specificity (%) | Does CADx reach the PIVI and/or SODA thresholds (excluding surveillance interval recommendations)? |
---|---|---|---|---|---|---|---|---|
2013 | Aihara et al.13 | AFE | 32 | 102 | 85 | 94 | 89 | PIVI, no; SODA, N/A |
2015 | Kuiper et al.14 | AFE (WavStat4) | 87 | 171 | 78 | 87 | 55 | PIVI, no; SODA, N/A |
2016 | Rath et al.15 | AFE (WavStat4) | 27 | 137 | 96 | 85 | 81 | PIVI, no; SODA, no |
2016 | Kominami et al.16 | Magnifying NBI | 41 | 88 | 93 | 93 | 93 | PIVI, yes; SODA, yes |
2018 | Mori et al.17 | Endocytoscopy with NBI | 325 | 466 | 96 | 95 | 92 | PIVI, yes; SODA, yes |
2019 | Horiuchi et al.18 | AFE, NBI and white light imaging | 95 | 429 | 95 | 85 | 96 | PIVI, no; SODA, yes |
2022 | Barua et al.10 | Endocytoscopy with NBI | 518 | 892 | 93 | 90 | 86 | PIVI, yes; SODA, yes |
2022 | Minegishi et al.19 | NBI | 181 | 395 | 94 | 95 | 76 | PIVI, yes; SODA, no |
2023 | Rondonotti et al.12 | Blue light imaging | 389 | 596 | 91 | 89 | 88 | PIVI, yes; SODA, no |
Histopathology assessments are used as the gold standard. ASGE, American Society for Gastrointestinal Endoscopy; ESGE, European Society of Gastrointestinal Endoscopy; PIVI, preservation and incorporation of valuable endoscopic innovations; SODA, simple optical diagnosis accuracy. PIVI 1, PIVI 2, SODA 1, SODA 2.
CADx, computer-aided diagnosis; NPV, negative predictive value; PIVI, preservation and incorporation of valuable endoscopic innovations; SODA, simple optical diagnosis accuracy; NA, not applicable; AFE, autofluorescence endocosopy; NBI, narrow-band imaging.